SCHEMBL6132350

SCHEMBL6132350

CC(C)(C)C1CCC(N2CCN(c3ccc(-c4ccc(C(=O)O)cc4)cc3)CC2)CC1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.74
KMT2A Q03164 2/20 0.74
USP2 O75604 1/20 0.52
CHEK1 O14757 2/20 0.49
ITGB3 P05106 1/20 0.48
ITGA2B P08514 1/20 0.48
TRPV6 Q9H1D0 1/20 0.47
ALOX15 P16050 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.44
MBTD1 Q05BQ5 1/20 0.44
TP53BP1 Q12888 1/20 0.44
L3MBTL4 Q8NA19 1/20 0.44
L3MBTL3 Q96JM7 1/20 0.44
KDM4E B2RXH2 5/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALDH1A1 P00352 2/20 0.42
OPRL1 P41146 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6132349 1.00 MEN1 (0.74) MEN1KMT2AUSP2CHEK1ITGB3
SCHEMBL6132932 0.96 MEN1 (0.80) MEN1KMT2AUSP2CHEK1ITGB3
SCHEMBL6135516 0.87 USP2 (0.67) MEN1KMT2AUSP2CHEK1ITGB3
SCHEMBL6134907 0.87 USP2 (0.67) MEN1KMT2AUSP2CHEK1ITGB3
SCHEMBL6134910 0.87 USP2 (0.67) MEN1KMT2AUSP2CHEK1ITGB3
SCHEMBL6132707 0.86 KMT2A (0.70) MEN1KMT2AITGB3ITGA2BTRPV6
SCHEMBL6132703 0.86 KMT2A (0.70) MEN1KMT2AITGB3ITGA2BTRPV6
SCHEMBL1305974 0.86 USP2 (0.63) MEN1KMT2AUSP2ITGB3ITGA2B
SCHEMBL6369559 0.84 USP2 (0.54) MEN1KMT2AUSP2CHEK1ITGB3
SCHEMBL6132600 0.84 KMT2A (0.59) MEN1KMT2AUSP2CHEK1ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6884774-B2 Cyclic hexapeptide derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-04-26 US disclosed
EP-1259535-B1 CYCLIC HEXAPEPTIDE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-04-13 EP disclosed
US-20030083238-A1 Cyclic hexapeptide derivatives ASTELLAS PHARMA INC. (JP) 2003-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083238-A1 Cyclic hexapeptide derivatives NGLY1, ALG1, CHIT1 MEN1 1517/4885KMT2A 4695/4885USP2 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.